Last reviewed · How we verify

NCT07299721: Brain Ultrafas

Brain Ultrafast Ultrasound Imaging

Not yet recruiting Last updated 23 December 2025
What this trial tests

trial testing Ultrafast ultrasound (UFUS) in CHD - Congenital Heart Disease in 300 participants. Not yet recruiting.

Timeline
1 January 2026
Primary endpoint
1 January 2026
1 January 2029

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment300
Start date1 January 2026
Primary completion1 January 2026
Estimated completion1 January 2029
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

Adults 0 to 2, any sex, with CHD - Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Congenital heart defects affect 1 in 100 births in France, with rising prevalence due to better care. Despite improved survival, 40% of children post-surgery face neurological impairments, and some of them show brain lesions. Causes include heart defects, genetic syndromes, and surgeries. Some heart defects and support systems increase cerebral risks. Monitoring cerebral perfusion is difficult to assess but emerging ultrafast ultrasound offers real-time, non-invasive blood flow insights.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for CHD - Congenital Heart Disease

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07299721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing